Equillium Inc (EQ) - News Archive

: Equillium Inc. a clinical-stage biotechnology firm focused on immunobiology for severe autoimmune and inflammatory disorders, has made notable strides recently. Notably, a poster was presented at the 39th Annual Meeti...

In a promising development for the field of immunology and transplantation, Equillium, Inc. (Nasdaq: EQ), has recently announced a favorable interim analysis from its Phase 3 EQUATOR study evaluating itolizumab in treat...

Equillium Demonstrates Promising Financial Growth and Advances in Immunotherapy ResearchEquillium, a leading clinical-stage biotechnology company specializing in the development of innovative therapeutics for severe aut...

LA JOLLA, CA Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company recognized for its innovative approach to developing therapeutics targeting severe autoimmune and inflammatory disorders, proudly announc...

Equillium Inc., a clinical-stage biotechnology company dedicated to developing novel therapeutics for severe autoimmune and inflammatory disorders, took part in the annual meeting of The American Association of Immunolo...